Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q3 2025 · 10-Q
Revenue$83.04M$83.04M−3.2% vs Q3 2024 Net Income-$501.00K-$501.00KN/M vs Q3 2024 EPS Diluted-$0.02-$0.02N/M vs Q3 2024 Operating Income-$6,804,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$7,797,000−54.0% Margins · derivedOperating margin-8.2%−14.1 pt vs Q3 2024
Net margin-0.6%−3.2 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 3, 2025 · 34 d after period end